161 related articles for article (PubMed ID: 11782903)
1. Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells.
Tran CD; Timmins P; Conway BR; Irwin WJ
J Pharm Sci; 2002 Jan; 91(1):117-28. PubMed ID: 11782903
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate.
Cummins CL; Mangravite LM; Benet LZ
Pharm Res; 2001 Aug; 18(8):1102-9. PubMed ID: 11587480
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies.
Engman HA; Lennernäs H; Taipalensuu J; Otter C; Leidvik B; Artursson P
J Pharm Sci; 2001 Nov; 90(11):1736-51. PubMed ID: 11745731
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
5. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
6. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
7. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
8. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
Schmiedlin-Ren P; Thummel KE; Fisher JM; Paine MF; Lown KS; Watkins PB
Mol Pharmacol; 1997 May; 51(5):741-54. PubMed ID: 9145912
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
von Richter O; Burk O; Fromm MF; Thon KP; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2004 Mar; 75(3):172-83. PubMed ID: 15001968
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.
Pfrunder A; Gutmann H; Beglinger C; Drewe J
J Pharm Pharmacol; 2003 Jan; 55(1):59-66. PubMed ID: 12625868
[TBL] [Abstract][Full Text] [Related]
12. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
13. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.
Bertilsson PM; Olsson P; Magnusson KE
J Pharm Sci; 2001 May; 90(5):638-46. PubMed ID: 11288108
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
Sun X; Tang S; Hou B; Duan Z; Liu Z; Li Y; He S; Wang Q; Chang Q
BMC Gastroenterol; 2021 Jan; 21(1):2. PubMed ID: 33407159
[TBL] [Abstract][Full Text] [Related]
15. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
Hochman JH; Chiba M; Nishime J; Yamazaki M; Lin JH
J Pharmacol Exp Ther; 2000 Jan; 292(1):310-8. PubMed ID: 10604964
[TBL] [Abstract][Full Text] [Related]
16. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
17. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
von Ahsen N; Richter M; Grupp C; Ringe B; Oellerich M; Armstrong VW
Clin Chem; 2001 Jun; 47(6):1048-52. PubMed ID: 11375290
[TBL] [Abstract][Full Text] [Related]
18. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180.
Aiba T; Susa M; Fukumori S; Hashimoto Y
Drug Metab Pharmacokinet; 2005 Aug; 20(4):268-74. PubMed ID: 16141606
[TBL] [Abstract][Full Text] [Related]
19. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4.
Takanaga H; Ohnishi A; Yamada S; Matsuo H; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
J Pharmacol Exp Ther; 2000 Apr; 293(1):230-6. PubMed ID: 10734174
[TBL] [Abstract][Full Text] [Related]
20. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.
Suzuki H; Sugiyama Y
Eur J Pharm Sci; 2000 Nov; 12(1):3-12. PubMed ID: 11121729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
